Journal article · 2024 · Open access

Turning foes to friends: Advanced “in situ nanovaccine” with dual immunoregulation for enhanced immunotherapy of metastatic triple-negative breast cancer

Ze Wang, Tong Sha, Jinwei Li, Huanyu Luo, Annan Liu, Liang Hao, Jinbiao Qiang, Lei Li, Andrew K. Whittaker, Bai Yang, Hongchen Sun, Ce Shi and 1 more

Bioactive Materials, 39, 612–629 · Published 31 May 2024 · DOI 10.1016/j.bioactmat.2024.04.023

Open full textCite this paper

In brief

“Turning foes to friends: Advanced “in situ nanovaccine” with dual immunoregulation for enhanced immunotherapy of metastatic triple-negative breast cancer” is a 2024 journal article by Ze Wang and 12 co-authors, published in Bioactive Materials. OpenAlex counts 53 citations as of 21 November 2026, which puts it in the top 4% of works published in 2024 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at Bioactive Materials.

Citations
53
Most cited in
2025 (29)
Field-weighted impact
4.49
References
45
Authors
13

Abstract

As a “cold tumor”, triple-negative breast cancer (TNBC) exhibits limited responsiveness to current immunotherapy. How to enhance the immunogenicity and reverse the immunosuppressive microenvironment of TNBC remain a formidable challenge. Herein, an “in situ nanovaccine” Au/CuNDs-R848 was designed for imaging-guided photothermal therapy (PTT)/chemodynamic therapy (CDT) synergistic therapy to trigger dual immunoregulatory effects on TNBC. On the one hand, Au/CuNDs-R848 served as a promising photothermal agent and nanozyme, achieving PTT and photothermal-enhanced CDT against the primary tumor of TNBC. Meanwhile, the released antigens and damage-associated molecular patterns (DAMPs) promoted the maturation of dendritic cells (DCs) and facilitated the infiltration of T lymphocytes. Thus, Au/CuNDs-R848 played a role as an “in situ nanovaccine” to enhance the immunogenicity of TNBC by inducing immunogenic cell death (ICD). On the other hand, the nanovaccine suppressed the myeloid‐derived suppressor cells (MDSCs), thereby reversing the immunosuppressive microenvironment. Through the dual immunoregulation, “cold tumor” was transformed into a “hot tumor”, not only implementing a “turning foes to friends” therapeutic strategy but also enhancing immunotherapy against metastatic TNBC. Furthermore, Au/CuNDs-R848 acted as an excellent nanoprobe, enabling high-resolution near-infrared fluorescence and computed tomography imaging for precise visualization of TNBC. This feature offers potential applications in clinical cancer detection and surgical guidance. Collectively, this work provides an effective strategy for enhancing immune response and offers novel insights into the potential clinical applications for tumor immunotherapy.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Wang, Z., Sha, T., Li, J., Luo, H., Liu, A., Hao, L., Qiang, J., Li, L., Whittaker, A. K., Yang, B., Sun, H., Shi, C., & Lin, Q. (2024). Turning foes to friends: Advanced “in situ nanovaccine” with dual immunoregulation for enhanced immunotherapy of metastatic triple-negative breast cancer. Bioactive Materials, 39, 612–629. https://doi.org/10.1016/j.bioactmat.2024.04.023

MLA 9

Wang, Ze, et al. “Turning foes to friends: Advanced “in situ nanovaccine” with dual immunoregulation for enhanced immunotherapy of metastatic triple-negative breast cancer.” Bioactive Materials, vol. 39, 2024, pp. 612–629. https://doi.org/10.1016/j.bioactmat.2024.04.023.

Chicago

Wang, Ze, Tong Sha, Jinwei Li, Huanyu Luo, Annan Liu, Liang Hao, Jinbiao Qiang, et al. 2024. “Turning foes to friends: Advanced “in situ nanovaccine” with dual immunoregulation for enhanced immunotherapy of metastatic triple-negative breast cancer.” Bioactive Materials 39: 612–629. https://doi.org/10.1016/j.bioactmat.2024.04.023.

Harvard

Wang, Z. et al. (2024) ‘Turning foes to friends: Advanced “in situ nanovaccine” with dual immunoregulation for enhanced immunotherapy of metastatic triple-negative breast cancer’, Bioactive Materials, 39, pp. 612–629. doi:10.1016/j.bioactmat.2024.04.023.

IEEE

Z. Wang et al., “Turning foes to friends: Advanced “in situ nanovaccine” with dual immunoregulation for enhanced immunotherapy of metastatic triple-negative breast cancer,” Bioactive Materials, vol. 39, pp. 612–629, 2024, doi: 10.1016/j.bioactmat.2024.04.023.

BibTeX

@article{wang2024turning,
  title     = {{Turning foes to friends: Advanced “in situ nanovaccine” with dual immunoregulation for enhanced immunotherapy of metastatic triple-negative breast cancer}},
  author    = {Wang, Ze and Sha, Tong and Li, Jinwei and Luo, Huanyu and Liu, Annan and Hao, Liang and Qiang, Jinbiao and Li, Lei and Whittaker, Andrew K. and Yang, Bai and Sun, Hongchen and Shi, Ce and Lin, Quan},
  journal   = {Bioactive Materials},
  year      = {2024},
  volume    = {39},
  pages     = {612--629},
  doi       = {10.1016/j.bioactmat.2024.04.023},
  url       = {https://doi.org/10.1016/j.bioactmat.2024.04.023}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202444
20252929
20262020

Its field-weighted citation impact is 4.49: it has been cited 4.49 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics

  • triple-negative breast cancer
  • metastatic breast cancer
  • cold tumors
  • immunosuppressive tumor microenvironment
  • photothermal therapy
  • chemodynamic therapy
  • nanozymes
  • R848

Work with this paper

Most-cited papers in Engineering

All highly cited Engineering papers

Questions about this paper

How do I cite this paper in APA style?

Wang, Z., Sha, T., Li, J., Luo, H., Liu, A., Hao, L., Qiang, J., Li, L., Whittaker, A. K., Yang, B., Sun, H., Shi, C., & Lin, Q. (2024). Turning foes to friends: Advanced “in situ nanovaccine” with dual immunoregulation for enhanced immunotherapy of metastatic triple-negative breast cancer. Bioactive Materials, 39, 612–629. https://doi.org/10.1016/j.bioactmat.2024.04.023

How many times has this paper been cited?

53 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Bioactive Materials: sign in and open the full text from this page.

Who wrote this paper?

Ze Wang, Tong Sha, Jinwei Li, Huanyu Luo, Annan Liu, Liang Hao, Jinbiao Qiang, Lei Li, Andrew K. Whittaker, Bai Yang, Hongchen Sun, Ce Shi and 1 more.

What is the DOI of this paper?

10.1016/j.bioactmat.2024.04.023, permanently at https://doi.org/10.1016/j.bioactmat.2024.04.023. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.